ROMAINVILLE, France, Nov. 15, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging, announced today that four posters on Sarconeos (BIO101), the Company’s lead drug candidate for the treatment of sarcopenia, have been accepted for presentation at the 9th International Conference on Cachexia, Sarcopenia and Muscle Wasting, being held December 10-11, 2016 in Berlin, Germany.
Stanislas Veillet CEO BIOPHYTIS, said: "Sarcopenia, or muscle wasting, is a growing problem as the world population continues to age and live longer. Having four poster presentations focusing on Sarconeos at a conference specifically tailored to and attended by key opinion leaders in muscular dystrophies is the perfect opportunity to showcase to key opinion leaders its method of action, clinical development, and patient outcomes observed to date.”
| Posters: | ||
| Title: | BIO101, a drug candidate targeting Mas receptor for the treatment of age-related muscle degeneration. From molecular target identification to clinical development. | |
| Authors: | Pierre Dilda1, Anne-Sophie Foucault1, Maria Serova1, Sissi On1, Sophie Raynal1, Stanislas Veillet1, Waly Dioh1, René Lafont1,2 | |
| 1 BIOPHYTIS, Parc Biocitech, 102 avenue Gaston Roussel, 93230 Romainville, France | ||
| 2 Sorbonne Universités, UPMC Univ Paris 06, CNRS - Institut de Biologie Paris Seine (BIOSIPE), 75005 Paris, France | ||
| Title: | Mechanism of action of BIO101, a Mas receptor activator: A drug candidate for the treatment of sarcopenia. | |
| Authors: | Maria Serova1, Sophie Raynal1, Sissi On1, Stanislas Veillet1, Waly Dioh1, Pierre Dilda1, René Lafont1,2 | |
| 1 BIOPHYTIS, Parc Biocitech, 102 avenue Gaston Roussel, 93230 Romainville, France | ||
| 2 Sorbonne Universités, UPMC Univ Paris 06, CNRS - Institut de Biologie Paris Seine (BIOSIPE), 75005 Paris, France | ||
| Title: | SARA-PK: A combined study of the safety and pharmacokinetics of BIO101 in healthy young and older volunteers after single ascending and multiple ascending oral doses for 14 days. | |
| Authors: | Waly Dioh, Susanna Del Signore, Philippe Dupont, Louiza Daudigny and Stanislas Veillet | |
| BIOPHYTIS, Parc Biocitech, 102 avenue Gaston Roussel, 93230 Romainville, France. | ||
| Title: | Electronically administered Patient Reported Outcomes (ePROs) in sarcopenic older patients – the SARA Clinical data Platform novel approach to Clinical Trials. | |
| Authors: | Susanna Del Signore1, 2, Gianluca Zia1, Stefania Del Signore1 and Waly Dioh2 | |
| 1 Bluecompanion ltd, London, United Kingdom. | ||
| 2 BIOPHYTIS, Romainville, France. | ||
About The Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD)
The Society on Sarcopenia, Cachexia, and Wasting Disorders was founded in 2008 on the initiative of Dr. Stefan D. Anker and Dr. John E. Morley, whose leadership and vision guided the expansion of clinical expertise and research in this field. The Society on Sarcopenia, Cachexia and Wasting Disorders is a non-profit scientific organization comprised of an international and multidisciplinary group of health-care professionals primarily active in these fields. The SCWD seeks to further research on cachexia and sarcopenia and wasting disorders and bring practical solutions to health-care teams worldwide grappling with treatment. The spectrum of clinical disorders represented by the SCWD Society includes, but is not limited to cachexia, sarcopenia, the syndrome of muscle wasting associated to cancer, COPD, diabetes, heart failure, aging and other chronic conditions. In recent years, there has been tremendous growth in new diagnostic information, pharmacological and nutritional treatments for wasting disorders, as well as a greater number of associated clinical trials.
About SARCONEOS (BIO101)
Sarconeos is a first in class drug candidate based on the activation of the Mas receptor (major player of the renin-angiotensin system) restoring muscular anabolism, inhibiting myostatin, that has demonstrated meaningful activity in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle, leading to loss of mobility in elderly people. This condition, for which no medical treatment currently exists, was first described in 1993 and has entered the International Classification of Diseases (M62.84) in 2016. It affects more than 50 million people worldwide.
About BIOPHYTIS:
BIOPHYTIS SA (www.BIOPHYTIS.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.
BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN:FR0012816825).
For more information: http://www.BIOPHYTIS.com
Disclaimer
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.BIOPHYTIS.com).
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.
| BIOPHYTIS Stanislas VEILLET CEO contact@BIOPHYTIS.com Tel : +33 (0) 1 41 83 66 00 | Milestones Press and investor relations Bruno ARABIAN barabian@milestones.fr Tel : +33 (0) 1 83 62 34 84 Mob : +33 (0) 6 87 88 47 26 | LifeSci Advisors Chris MAGGOS Managing Director, Europe chris@lifesciadvisors.com Tel : +41 79 367 6254 | |
| Citigate Dewe Rogerson International press Laurence BAULT/Antoine DENRY Laurence.bault@citigate.fr/antoine.denry@citigate.fr Tel : +33 (0)1 53 32 84 78 Mob : +33(0)6 64 12 53 61 |